Background Somatic mutations in the epidermal growth factor receptor (EGFR) intracellular signalling pathways predict non-response to cetuximab in the treatment of advanced colorectal cancer (aCRC). We hypothesised that common germline variants within these pathways may also play similar roles. Methods We analysed 54 potentially functional, common, inherited EGFR pathway variants in 815 patients with aCRC treated with oxaliplatinfluoropyrimidine chemotherapy plus cetuximab. Primary endpoints were response and skin rash (SR). We had >85% power to detect ORs=1.6 for variants with minor allele frequencies >20%. Results We identified five potential biomarkers for response and four for SR, although none remained significant after correction for multiple testing. Our initial data supported a role for Ser313Pro in PIK3R2 in modulating response to cetuximab-in patients with KRAS wild-type CRCs, 36.4% with one allele encoding proline responded, as compared with 71.2% homozygous for allele encoding serine (OR 0.23, 95% CI 0.09 to 0.56, p=0.0014), and this association was predictive for cetuximab (p interaction =0.017); however, independent replication failed to validate this association. No previously proposed predictive biomarkers were validated. Conclusions Our study highlights the need to validate potential pharmacogenetic biomarkers. We did not find strong evidence for common germline biomarkers of cetuximab response and toxicity.
InTRoduCTIon
The treatment of colorectal cancer (CRC) is improving with average survival for advanced CRC (aCRC) increasing from ~6 months with best supportive care alone, to 10-12 months with fluoropyrimidine-based regimens, 1 and up to 16-21 months with oxaliplatin or irinotecan and a fluoropyrimidine. 2 3 In addition, monoclonal antibodies (McAbs) against the epidermal growth factor receptor (EGFR) improve overall survival (OS) in patients with aCRC in whom other treatments have failed 4 and, in combination with first-line therapy, in those with RAS wild-type tumours. 5 EGFR acts as a gateway for the Ras-Raf-MAP and PI3K-PTEN-Akt intracellular signalling pathways. The efficacy of cetuximab and panitumumab (anti-EGFR McAbs) is dependent on an absence of somatic mutations in members of this signalling cascade such as KRAS 6 and NRAS, 5 and these predictive biomarkers help guide the treatment of aCRC. 7 Inherited factors are also likely to affect response to, and side effects from, chemotherapy and biological therapy. Pro241 in CCND1, 8 61A>G in EGF, 8 9 His131Arg in FCGR2A, 10 Val158Phe in FCGR3A, 10 11 765G>C and +8473T>C in PTGS2, 12 and Arg521Lys 13 and a (CA) n repeat 11 14 in EGFR have all been suggested to predict response to cetuximab.
The UK MRC COIN Trial (NCT00182715), which consists of 2445 patients with aCRC treated with oxaliplatin-fluoropyrimidine chemotherapy with or without cetuximab, serves as an important resource for the discovery of new, and validation of existing, genetic biomarkers. 15 16 We used this resource, together with patients from the allied COIN-B trial of oxaliplatin-fluoropyrimidine chemotherapy plus cetuximab (NCT00640081), 17 to investigate the role of 54 potentially functional, common, inherited EGFR-related variants in predicting response to, and side effects from, cetuximab.
MeThodS

Patients and treatments
All patients had metastatic or locally advanced colorectal adenocarcinoma and received no previous chemotherapy for advanced disease. All patients gave fully informed consent for this study (approved by REC [04/MRE06/60]). COIN patients were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine chemotherapy (arm A), continuous chemotherapy plus cetuximab (arm B) or intermittent chemotherapy (arm C). 15 16 COIN-B patients were randomised 1:1 to receive intermittent chemotherapy and cetuximab (arm D) or intermittent chemotherapy and continuous cetuximab (arm E) (see online supplementary figure). 17 
ShORt REPORt
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Cancer genetics Selection and genotyping of potential pharmacogenetic variants
Potentially functional inherited variants were sought in 146 genes identified from literature reviews as likely to play a role in the EGFR signalling pathways. Variants were considered potentially functional if there was previous clinical or biological evidence for an effect on response or side effects, if they were non-synonymous or if they occurred in the promoter region. Variants were mined from dbSNP (v.129, http://www. ncbi. nlm. nih. gov/ SNP/) and from exome re-sequencing germline data, and those with a minor allele frequency (MAF) >5% (Caucasian population) were considered for genotyping. Genotyping was carried out using a custom Illumina GoldenGate assay or by in-house assays (see online supplementary information).
Independent analysis of Ser313Pro in PIK3R2
We obtained germline DNA samples together with response data for 309 unrelated patients with KRAS wild-type CRCs that were treated with cetuximab alone or in combination with chemotherapy. These were previously collected as part of an international consortium study. 18 We carried out PCR amplification using the primers 5′-GGG CCGT AAAT ACTG ATCCCT-3′ and 5′-TCCAACATTGGGACTGCCGA-3′ and directly sequenced the purified products. In total, 81.9% (n=253) of samples were successfully amplified and genotyped.
Clinical parameters assessed
The primary endpoints were: (1) 12-week response, defined as complete response or partial response versus stable disease or progressive disease at 12 weeks and (2) grade ≥2 skin rash (SR) or cetuximab dose reduction or delay due to SR versus grade <2 SR with no cetuximab dose modification. Response was assessed using RECIST criteria and SR toxicity was graded using NCI Common Terminology Criteria version 3.0.
19 Secondary efficacy endpoints were OS and overall response rate (ORR), and secondary toxicity endpoints were grade ≥2 at any point versus grade <2 for lethargy, nausea or vomiting, diarrhoea, stomatitis, hand-foot syndrome (HFS), hypomagnesaemia and nail changes.
Sample size and power considerations
Patients from COIN arm B and COIN-B (those treated with cetuximab) had similar efficacy and toxicity outcomes at 12 weeks, so were combined to increase power, as were patients from COIN arms A and C (no cetuximab). A total of 2183 patients were genotyped, of which 815 received cetuximab (676 had a response outcome and 730 had a SR outcome) and 1368 did not receive cetuximab (1169 had a response outcome). Based on 676 patients (received cetuximab, genotyped and with data on response), we had >85% power (p<0.05) to detect an OR of 1.6, equating to a 12% difference in response or SR (45% responded or had SR) for a variant with a MAF >20%, and an OR of 2.3, corresponding to a 20% difference in response or SR, for a variant with a MAF >5%.
Statistical analyses
Genotypes were tested for deviation from the Hardy-Weinberg equilibrium (HWE) using a χ 2 test with p<9.3×10 −4 (multiple testing for n=54 variants). Pharmacogenetic analyses were carried out using Stata V.12.1 with a codominant model, and tested using the likelihood-ratio χ 2 statistic. For significant associations (p<0.05), subsequent analyses were carried out using logistic regression under the best-fitting allele model and adjusted for the type of fluoropyrimidine. Correction for multiple testing was by Bonferroni.
ReSulTS
We extracted DNA from peripheral blood samples from 2183 unrelated patients with aCRC from the UK national trials COIN (2070 of the 2445 randomised) and COIN-B (113 of the 226 randomised). All patients received oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab as continuous or intermittent regimen. For the first 12 weeks, at which point the primary pharmacogenetic analyses were carried out, treatments were identical in all patients apart from the choice of fluoropyrimidine (n=834, 38% received OxMdG and n=1349, 62% received Xelox) together with the randomisation of chemotherapy alone or in combination with cetuximab (n=815, 37% received cetuximab) (see online supplementary figure and supplementary table S1). Here, we focused on the analysis of the 815 patients treated with cetuximab, to identify predictive biomarkers for this biological therapy ( figure 1) .
Eighty potentially functional, common (MAFs>5%), inherited, coding and promoter-region variants were identified in the EGFR pathway. Of these, 71 passed in silico locus conversion on the GoldenGate platform and 51 were successfully assayed. Four variants were assayed 'in house' of which three were successfully genotyped. No genotypes deviated from the HWE. Therefore, in total, 54 variants were considered for the analyses of response to, and side effects from, cetuximab (see online supplementary table S2; figure 1 ).
Primary analyses for response
Five variants were associated with response (p<0.05), the most significant being a non-synonymous variant (Ser313Pro) in the phosphatidylinositol 3-kinase regulatory (PIK3R) subunit 2 ( We analysed Ser313Pro in PIK3R2 in patients with KRAS wildtype CRCs who did not receive cetuximab (from arms A and C of COIN), and observed a predictive effect for response to cetuximab (p interaction =0.017, see online supplementary table S4).
We sought independent evidence for a predictive role of Ser313Pro by analysing germline DNA samples from 309 unrelated patients with KRAS wild-type CRCs that were treated with cetuximab. We had >90% power to observe an OR 0.23 equating to a 35% difference in response (found in COIN). We did not find any effect on objective response, with an allelic trend in the opposite direction: 45.8% (11/24) of patients with one allele encoding proline had a response, as compared with 32.2% (68/211) of patients homozygous for alleles encoding serine (p=0.18).
Arg268Trp in PLCG2 was also associated with response in COIN/COIN-B (OR=1.66, 95% CI 1.03 to 2.67, p=0.037) and was predictive for cetuximab (p interaction =0.001; table 1); however, this effect was only significant in the KRAS mutant subset (p interaction =0.034; see online supplementary table S5) and was not significant after correction for multiple testing.
Primary analyses for SR
Four variants were associated with SR (p<0.05), the most significant being Asn283Lys in PIK3R3 (table 1; see online supplementary table S3 ); 56.8% of patients with at least one allele encoding lysine had severe SR as compared with 45.7% of patients homozygous for alleles encoding asparagine (OR 1.56, 95% CI 1.17 to 2.10, p=0.003). This association was predictive for cetuximab (p interaction =0.014; table 1); however, no associations remained significant after correction for multiple testing. There was no interaction with the type of fluoropyrimidine used (p=0.66).
Previously proposed predictive biomarkers
Numerous germline variants in the EGFR pathway have been suggested to be predictive biomarkers for cetuximab response. [8] [9] [10] [11] [12] [13] [14] These were tested as part of our study and only c.1-382A>G (61A>G) in EGF and c.1812+430T>C in PTGS2 were significantly associated with response (p=0.008 and 0.010, respectively), and trended towards (p interaction =0.07), or had a significant (p interaction =0.046), predictive effect for cetuximab (irrespective of KRAS status), respectively (table 1) . However, neither were Figure 1 CONSORt diagram of the study design and analyses. Shown are the numbers of variants analysed, together with the numbers of patients studied, and the primary and secondary endpoints. EGFR, epidermal growth factor receptor; MAF, minor allele frequency; ORR, overall response rate; OS, overall survival; pts, patients; SR, skin rash.
Cancer genetics
predictive in the KRAS wild-type subset (p interaction =0.17 and 0.21, respectively; table 1).
Secondary analyses
Ser313Pro in PIK3R2 was associated with OS and ORR, Cys141Phe in EREG with ORR and Asp784Val in EGF with OS (see online supplementary table S6). Val906Ile in MAP3K1 was associated with lethargy, His321Arg in RASAL1 and Arg574Pro in MMP9 with nausea/vomiting, Lys344Thr in RPS6KA1 and Val906Ile in MAP3K1 with diarrhoea, Arg298His in PTGES2, Met322Thr in TSC1, Phe212Val in FCGR3A and c.1-1671insA in MMP3 with stomatitis, c.1-382 A>G in EGF, Pro1170Ala in ERBB2, Cys141Phe in EREG and Asp806Asn in MAP3K1 with HFS, Tyr187His in DUSP1 with hypomagnesaemia and Arg335Cys in IL8RA, Glu920Val in EGF and Lys220Arg in PLAUR with nail changes (see online supplementary table S7). None of the associations remained significant after correction for multiple testing.
dISCuSSIon
In total, we analysed 54 inherited variants from genes in the EGFR-related pathways for a potential role in response to, or side effects from, cetuximab in the treatment of aCRC. Given the size of our cohort, we had considerable power to detect common alleles of small effects. Although we identified five potential biomarkers for response and four for SR in our primary analyses, none remained significant after adjusting for multiple testing. Numerous common inherited biomarkers for cetuximab response have been proposed by others [8] [9] [10] [11] [12] [13] [14] ; however, many of these have been derived from studies using small cohorts of patients and, consequently, the majority have failed, 14 or have been inconsistent on independent replication. 12 14 18 20 In our study, we analysed these variants and had limited evidence for c.1-382A>G (61A>G) in EGF and c.1812+430T>C (+8473T>C) in PTGS2 in predicting response to cetuximab. However, neither effect was found in the important KRAS wild-type subset (which had the potential to respond), and our data did not support the proposed direction of allelic effect for c.1-382A>G. 12 14 Therefore, we have no strong evidence for a predictive role for any of these variants.
Our study clearly highlights the need to validate potential pharmacogenetic biomarkers. Initial data from our study strongly supported a role for Ser313Pro in PIK3R2 in modulating response to cetuximab and this association was only significant in those patients with CRCs that were wild type for KRAS, so had the potential to respond, and was not found in patients who did not receive cetuximab, regardless of their KRAS status, so was unlikely to be a prognostic effect. However, we carried For endpoints: (+) patients who responded or had SR; (−) patients who did not respond or have SR. A and B alleles were assigned by Illumina; the common allele encodes the wild-type amino acid, so for Ser313Pro the B allele encodes Ser and for Asn283Lys the A allele encodes Asn. NA, for overdominant model and SR is unlikely to be related to the tumour molecular profile. No associations were significant after correction for multiple testing. *Results shown using a codominant model. †Results shown using ORs and 95% CIs with the best model that fitted the data (models for (d) = dominant allele, (r) = recessive allele, (a) = additive allele, (od) = overdominant allele).
‡Patients not treated with cetuximab were from arms A and C of COIN. df, degrees of freedom; NA, not applicable; SR, skin rash.
out a well-powered independent analysis of unrelated patients and failed to validate our initial observations, suggesting that this was a chance event.
In conclusion, we have carried out a comprehensive, welldesigned study to identify common germline biomarkers for cetuximab-related outcomes, but failed to establish strong evidence for their existence.
